News and reporting on cancer immunotherapy.
Insight's portfolio includes a gene expression-based immuno-oncology assay for therapy response prediction.
The researchers are aiming to provide new insights as to which cancer patients will respond best to immunotherapy based on their genetic backgrounds.
In two trials in the neoadjuvant setting reported at SABCS, one showed improved rates of pathologic complete response with added immunotherapy, and the other showed no difference.
Researchers tested the combined treatment in mice, after detecting increased PAK4 expression and reduced immune infiltration in melanoma patients with poor anti-PD-1 response.
The company is using the test to direct patient enrollment and treatment stratification in a trial of pembrolizumab (Keytruda) combination treatments.
The partners plan to employ Personalis' ImmunoID NeXT platform to investigate biomarkers of response and mechanisms of resistance to cancer therapies.
The company is hoping that the comprehensive solution will help bring on more pharma customers and offer extended opportunities for current users.
In a survey conducted by an association working group, 40 percent of respondents said they are already offering TMB, with most others planning to do the same within the year.
The firms will codevelop companion diagnostics for anti-PD1/PD-L1 immunotherapy treatments for cancer.
The company has signed technology deals with Repertoire Genesis of Japan, Stratifyer Molecular Pathology of Germany, and the University of Bonn.
According to NPR, an antibody-based test could identify people who were exposed to SARS-CoV-2 and either didn't develop symptoms or were misdiagnosed.
A sequencing analysis of New York City rats indicates they have adapted to the urban environment there, according to a recent preprint.
Ars Technica reports that a multicellular eukaryotic parasite has lost its mitochondria.
In Science this week: perspective piece says AI can accelerate drug discovery by using genomic and chemical data, and more.